Methylene blue (MB), a synthetic compound first developed in the late 1800s, has gained popularity recently due to emerging interest in its potential neuroprotective and antioxidant properties. Some early research and anecdotal use suggest it may support mitochondrial function and cognitive health, which has led to increased public curiosity. While it has long been used in medical settings for conditions like methemoglobinemia and urinary tract procedures, pharmacies should be aware of growing off-label interest and ensure patients understand its appropriate, evidence-based use and safety considerations.
For community pharmacists, this trend represents not just a clinical topic but a potential business opportunity. Understanding the science, safety, and evolving market landscape of methylene blue is essential.
Traditional and emerging uses of methylene blue
FDA-approved uses:
Treatment of methemoglobinemia
Methylene blue is FDA-approved for the treatment of methemoglobinemia, a rare blood disorder where hemoglobin is unable to release oxygen effectively to body tissues. It works by converting methemoglobin back to normal hemoglobin, restoring its oxygen-carrying capacity. Dosing is typically around 1–2 mg/kg intravenously.
Diagnostic dye
Methylene blue is used as a visualizing agent during surgeries and diagnostic procedures to stain tissues or highlight anatomical structures or to detect fistulas, locate ureteral orifices, or trace fluid movement.
Emerging and off-label uses:
Methylene blue has gained attention for several emerging and off-label uses, largely driven by early research, theoretical mechanisms, and anecdotal reports. These uses are not FDA-approved and should be approached with caution, particularly due to dosage concerns and potential drug interactions.
Cognitive enhancement & neuroprotection
Methylene blue has been proposed to improve memory, focus, and mental clarity. A study published in Radiology showed enhanced memory retrieval in healthy adults after a single dose. It is believed to support mitochondrial function and increase ATP production, which may contribute to its cognitive benefits.
Additionally, studies have shown methylene blue has a role in treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, with some preclinical studies suggesting it may reduce oxidative stress and support overall neuronal health.
Mitochondrial & metabolic support
There is growing interest in methylene blue as a mitochondrial enhancer, particularly for conditions such as chronic fatigue, fibromyalgia, and long COVID. It is thought to help improve cellular energy metabolism, which may contribute to its potential benefits in managing these energy-related disorders.
Adjunct in psychiatric conditions
Methylene blue is being explored in small studies as an adjunct therapy for depression and bipolar disorder. Its proposed mechanism involves modulating monoamine oxidase activity and reducing oxidative damage, which may contribute to its potential mood-stabilizing effects.
Antimicrobial and Antiviral Effects
Methylene blue has shown some potential as an antiviral agent and is being used experimentally in light-activated treatments against drug-resistant bacteria and fungi. It has also been investigated for possible use in treating malaria and urinary tract infections, highlighting its broad antimicrobial properties.
Safety considerations and drug interactions
When using methylene blue, it’s important to be aware of potential safety concerns and drug interactions. Below are key considerations to keep in mind:
- Risk of serotonin syndrome when combined with SSRIs or other serotonergic drugs
- Can interfere with pulse oximetry readings, potentially affecting oxygen saturation monitoring
- Dosing is critical – excessive doses can be toxic
- Contraindications: Avoid use in patients with G6PD deficiency due to risk of hemolysis
- Side effects: Nausea, dizziness, hemolysis at high doses, and green-blue urine or stool discoloration
The business side of methylene blue
With growing attention from biohackers, wellness influencers, and longevity enthusiasts, methylene blue is emerging as a high-profile supplement and compound. As interest increases, many pharmacies are considering whether to stock or compound it to meet rising patient inquiries and market demand.
Growing demand in functional and integrative medicine
Market trends from 2023 to 2024 indicate a surge in consumer interest in methylene blue, driven in part by influential figures such as RFK Jr. and popular wellness podcasts that promote its potential benefits for mental clarity and anti-aging. In response to this growing demand, compounding pharmacies are experiencing an uptick in requests for customized MB formulations, including oral troches, nasal sprays, and sublingual drops.
Retail and supplement market
Over-the-counter “nootropic” brands are selling methylene blue (MB) supplements online, but many of these products are not pharmaceutical grade. A 2022 Journal of Pharmaceutical Sciences quality analysis found that some contain contaminants or are misbranded. This presents a competitive opportunity for community pharmacists to offer properly compounded, pharmacist-vetted alternatives.
Sourcing and concerns
When it comes to human consumption, not all methylene blue is created equal. Only pharmaceutical-grade methylene blue should be used, as lower-grade alternatives—such as chemical reagent or aquarium-grade—can contain harmful impurities like heavy metals. To ensure both safety and regulatory compliance, it’s critical that the product meets United States Pharmacopeia (USP) standards. Vetting suppliers is equally important; they must provide thorough documentation, including lot numbers and certificates of analysis (COAs), to verify product integrity and maintain compliance.
Pricing and profitability
The average cost for pharmaceutical-grade methylene blue (MB) powder ranges from $250 to $500 per 25g, depending on its purity. Custom compounds—such as 1mg capsules or 0.5mg/mL drops—can be priced based on labor and materials, often yielding high margins when there is steady demand. Margins typically range from 3x to 10x, particularly for customized compounding or niche wellness applications.
Profitability is driven by several key factors:
- Low dose-per-use, which extends product supply
- High perceived value in markets like biohacking, nootropics, and longevity
- Limited competition, especially for pharmacies offering compounding services
What community pharmacists should do
As interest in methylene blue (MB) grows—particularly for its off-label potential in neurological health, antimicrobial applications, and mitochondrial support—pharmacies may encounter more patient inquiries and opportunities to provide guidance or access. However, due to its pharmacological potency and risk profile, MB must be approached with caution and clinical discernment. This section outlines key considerations for safely educating patients, evaluating potential service offerings, and staying informed in a rapidly evolving space.
Watch for red flags
Conduct thorough medication reviews and medical history checks before initiating methylene blue therapy. Pay special attention to the use of SSRIs (Selective Serotonin Reuptake Inhibitors) and MAOIs (Monoamine Oxidase Inhibitors), as methylene blue is a potent monoamine oxidase inhibitor itself and can significantly increase the risk of serotonin syndrome. Additionally, screen patients for G6PD (glucose-6-phosphate dehydrogenase) deficiency, as methylene blue can cause hemolytic anemia in individuals with this condition. Consider other potential contraindications such as renal impairment or known hypersensitivity to thiazine dyes.
Evaluate opportunities
Pharmacies should assess whether offering MB—either through compounding or resale—aligns with their operational capacity, regulatory permissions, and strategic goals. For compounders, confirm that your facility meets the necessary standards for sterile or non-sterile compounding of methylene blue formulations, and that you have access to validated sources of pharmaceutical-grade methylene blue. For those considering resale, verify that the product is properly labeled, traceable, and compliant with FDA and state board regulations. Evaluate your team’s training, inventory management systems, and patient education capabilities before moving forward.
Monitor industry updates
Stay informed on developments that may impact your methylene blue offerings. This includes FDA communications such as drug safety alerts, compounding guidelines, or enforcement actions; supplier changes that could affect availability or quality; and emerging research regarding new indications, dosing protocols, or adverse events related to MB. Subscribing to professional pharmacy bulletins, clinical research journals, and regulatory updates ensures your practice remains compliant and evidence-based.
Educate patients
Clearly communicate the importance of using pharmaceutical-grade methylene blue to ensure safety, efficacy, and consistency. Inform patients about the risks associated with purchasing from unverified or non-medical sources—such as industrial-grade products or supplements sold online—which may contain contaminants, incorrect dosages, or inconsistent purity levels. Reinforce that methylene blue should only be used under the guidance of a qualified healthcare professional, especially when considered for off-label use.
Need assistance communicating and promoting your offerings to patients?
Schedule a demo today to learn more about Lumistry’s Patient Relationship Management Platform and Marketing Services and how these solutions can help you stand out from the competition.
